GIA
BBNX

Gladstone Institutional Advisory’s Beta Bionics BBNX Stock Holding History

Gladstone Institutional Advisory’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Buy
14,201
+1
+0% +$12 0.01% 834
2026
Q1 		$142K Hold
14,200
– – 0.01% 811
2025
Q4 		$433K Hold
14,200
– – 0.02% 529
2025
Q3 		$282K Hold
14,200
– – 0.01% 667
2025
Q2 		$207K Buy
+14,200
New +$201K 0.01% 709

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Gladstone Institutional Advisory's BBNX Position: Q2 2026 in Review

Gladstone Institutional Advisory increased its Beta Bionics (BBNX) stake by 0.01% in Q2 2026, buying an estimated $12 and bringing the position to 14,201 shares worth $223K. The position accounts for 0.01% of the portfolio, ranked #834.

Gladstone Institutional Advisory first reported a position in BBNX in Q2 2025 and has held it in 5 quarters since. The position peaked at $433K in Q4 2025. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Gladstone Institutional Advisory held 14,201 shares of Beta Bionics worth $223K as of Q2 2026.
  • Gladstone Institutional Advisory bought 1 Beta Bionics share in Q2 2026, an estimated $12.
  • Beta Bionics made up 0.01% of Gladstone Institutional Advisory's portfolio in Q2 2026, its #834 holding.
  • Gladstone Institutional Advisory first reported a position in Beta Bionics in Q2 2025 and has held it in 5 quarters since.
  • Gladstone Institutional Advisory's Beta Bionics position peaked at $433K in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Gladstone Institutional Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.